Free Trial

Synthetic Biologics (SYN) News Today

Synthetic Biologics logo
Q3 2024 Exelixis Inc Earnings Call
Revisiting Humacyte
Old-Line Rheum Drugs Lose Luster in JIA
AI Simulations Help Drug Trials
GenScript Appoints New Board Members to Drive Global Growth
NanoSyrinx secures funds to develop biologic therapeutics
Telesis Bio Plans to Delist its Securities from The Nasdaq Stock Market
Noble Financial Sticks to Its Hold Rating for MustGrow Biologics (MGROF)
Truist Financial Sticks to Its Buy Rating for AbSci (ABSI)
Federal Regulation of Psychedelic Therapies
Humacyte co-founder now CEO of Durham startup
MustGrow Biologics (MGROF) Receives a Hold from Noble Financial
How Is Ulcerative Colitis Treated?
TD Cowen Reaffirms Their Buy Rating on AbSci (ABSI)
Get Synthetic Biologics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SYN and its competitors with MarketBeat's FREE daily newsletter.

Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)

Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…

Get Your Free Gold Guide

SYN Media Mentions By Week

SYN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

SYN
News Sentiment

0.35

0.47

Average
Medical
News Sentiment

SYN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

SYN Articles
This Week

1

3

SYN Articles
Average Week

Get Synthetic Biologics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SYN and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NYSEAMERICAN:SYN) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners